INIS
patients
100%
stem cells
67%
cancer
57%
tumors
55%
myeloid leukemia
54%
diseases
46%
vitamin c
43%
natural killer cells
42%
induction
36%
ascorbic acid
32%
dendrites
32%
humans
28%
grafts
27%
levels
23%
risks
22%
breasts
21%
cost
21%
netherlands
21%
mice
20%
antigens
20%
vaccines
19%
chemotherapy
18%
administration
18%
host
16%
therapy
16%
immunity
16%
transplants
15%
recovery
14%
cyclophosphamide
14%
blood
13%
Keyphrases
Acute Myeloid Leukemia
54%
Natural Killer Cells
52%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
47%
Vitamin C
43%
Haploidentical Transplantation
32%
Ascorbic Acid
32%
Minimal Residual Disease
26%
Alloreactive
25%
Hematopoietic Stem Cell Transplantation
22%
Natural Killer
22%
Dendritic Cells
21%
Dendritic Cell Vaccine
21%
Netherlands
21%
Graft-versus-host Disease (GvHD)
20%
Antitumor Effect
20%
Unrelated Donor
20%
Myeloma
18%
Intensive Chemotherapy
17%
Post-transplantation Cyclophosphamide (PTCy)
16%
T Cells
15%
Alloreactivity
15%
Donor Type
14%
Neutrophil Recovery
14%
Leukemia Patients
14%
Overall Survival
13%
Haploidentical Hematopoietic Stem Cell Transplantation
13%
Tumor
13%
Tumor-specific
12%
Single Center
12%
Interferon-γ
12%
Medicine and Dentistry
Acute Myeloid Leukemia
54%
Neoplasm
39%
Ascorbic Acid
32%
Natural Killer Cell
32%
Minimal Residual Disease
26%
Cyclophosphamide
24%
T Cell
22%
Breast Cancer
21%
Hematopoietic Stem Cell Transplantation
19%
Malignant Neoplasm
17%
Placebo
14%
Autologous Stem Cell Transplantation
14%
Cell Therapy
13%
Stem Cell Therapy
11%
Induction Chemotherapy
11%
Alloimmunity
11%
Overall Survival
11%
Dendritic Cell Vaccine
10%
Phase II Trials
10%
Lenalidomide
10%
Myeloma
10%
Haploidentical Transplantation
10%
Systematic Review
10%
Immunotherapy
10%
Acute Myelogenous Leukemia
10%
Risk Stratification
10%
Leukemia
10%
Neutrophil
10%
Middle Age
10%
Celecoxib
10%